Kyndryl Collapses On Accounting Review, CFO Exit As Analysts Brand IBM-Spinoff A “Disaster”
Shares in Kyndryl, an IBM spinoff and IT infrastructure services provider, crashed on Monday after the company warned investors that it is reviewing certain accounting practices amid an inquiry from the Securities and Exchange Commission. The company also posted third-quarter results that missed Bloomberg Consensus estimates and disclosed what JPMorgan analysts described as a “surprise” departure of its CFO.
Kyndryl stock crashed as much as 57%, its biggest one-day drop on record. Shares traded at their lowest level since November 2022 after the company disclosed an SEC inquiry into certain accounting practices.
In a filing, Kyndryl said it “anticipates reporting material weaknesses in the Company’s internal control over financial reporting for the period covered in the Quarterly Report, as well as for the full fiscal year ended March 31, 2025, and the first two fiscal quarters of fiscal year 2026.”
This is “expected to include, but may not be limited to, the effectiveness and strength of certain functions at the Company, including with respect to controls related to information and communication and tone at the top,” the filing noted.
The information technology services provider that works with hyperscalers also announced that CFO David Wysher and general counsel Edward Sebold had left the company.
On top of that, third-quarter results missed Bloomberg consensus estimates, and the company lowered its full-year outlook for both adjusted EBITDA margin and adjusted pretax profit.
Here’s a snapshot of the third-quarter (courtesy of Bloomberg):
Adjusted EPS 52c vs. 51c y/y, estimate 61c (Bloomberg Consensus)
Revenue $3.86 billion, +3.1% y/y, estimate $3.89 billion
- US revenue $958 million, estimate $982.3 million
- Japan revenue $568 million, estimate $588.8 million
Adjusted Ebitda $696 million, -1.1% y/y, estimate $701.2 million
Adjusted Ebitda margin 18%, estimate 18%
Adjusted pretax profit $168 million, estimate $192.4 million
Full-Year Forecast:
Sees adjusted Ebitda margin 17.5%, saw about 18%
Sees adjusted pretax profit $575 million to $600 million, saw at least $725 million
Kyndryl CEO Martin Schroeter declined to comment during the earnings call:
“The fact is we just can’t comment until the examination is complete. The teams are working expeditiously so we can share a remediation plan.”
Kyndryl said it needs additional time to finalize its fiscal third-quarter report and noted that it is preparing a remediation plan, which will be detailed in the upcoming filing.
Analysts at JPMorgan downgraded Kyndryl to Underweight from Overweight and slashed their price target to $16 from $40. They told clients the downgrade was due to cuts to sales and profit guidance, the CFO’s surprise departure, and the delayed quarterly filing.
Bloomberg Intelligence analysts said, “Kyndryl faces secular pressure in infrastructure services and new guidance is for a revenue decline in fiscal 2026, raising doubts about the durability of its turnaround.”
“KD was a disaster, with a miss-and-cut report, several mgmt. changes, and a delayed 10Q filing,” Vital Knowledge analysts wrote in a note.
Tyler Durden Mon, 02/09/2026 – 11:45
Source: https://freedombunker.com/2026/02/09/kyndryl-collapses-on-accounting-review-cfo-exit-as-analysts-brand-ibm-spinoff-a-disaster/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


